We are thankful for the comments on ‘Sodium glucose co-transporter (SGLT2) inhibitor: Patient safety and clinical importance’, and we appreciate the concern raised for its risk of euglycemic diabetic ketoacidosis (DKA). During clinical development programs for a new drug approval, it is not uncommon that some unexpected safety issues may go unobserved. Interestingly, the incidence of ketoacidos...

Adults treated with empagliflozin (Jardiance—Boehringer Ingelheim, Lilly) during hospitalization for an acute heart failure (HF) event had reduced all-cause mortality, fewer HF events, and improvement in HF–related symptoms compared those given a placebo, according to results of the EMPULSE trial presented at 2021 American Heart Association (AHA) Scientific Sessions. These data add broader info...

Aim: This study aimed to examine the effects of sodium glucose cotransporter 2 inhibitors (SGLT-2i) on lipid levels at 12 weeks follow-up in newly diagnosed hypertensive (NDHT) patients with type diabetes mellitus (T2DM). Methodsː retrospective study, 236 NDHT T2DM were included. The SGLT-2i group consisted who received (empagliflozin or dapagliflozin) addition stable triple combination treatme...

At online scientific expert meeting of the South region held on October 3, 2020, results international multicenter study EMPEROR-Reduced were discussed. Number proposals and recommendations adopted for further cardiovascular renal effects empagliflozin, its use in clinical practice patients with chronic heart failure.

AimsTo assess the long-term cost-effectiveness of novel glucagon-like peptide-1 (GLP-1) analog oral semaglutide versus sodium-glucose cotransporter-2 inhibitor empagliflozin, dipeptidyl peptidase-4 sitagliptin and injectable GLP-1 liraglutide in Netherlands, based on results PIONEER clinical trials.MethodsOutcomes were projected over patient lifetimes using IQVIA CORE Diabetes Model. Clinical d...

Backgroundː In this study, we aimed to examine the effect of Sodium Glucose Cotransporter 2 inhibitors (SGLT-2i) on routine laboratory test results at 12 weeks follow-up among type diabetes mellitus (T2D) patients using empagliflozin and dapagliflozin. Methodsː Three hundred ten with a diagnosis T2D (over 18 years age) SGLT-2i added stable triple combination therapy were included in study. Pati...